Geron Corp. shares jumped after the biotech company said the New England Journal of Medicine was going to publish two papers showing positive results for its drug imetelstat. Geron shares jumped 19% to $3.64. In two mid-stage clinical trials, Geron said the use of imetelstat suggested it works against malignant cells that cause essential thrombocythemia, a disease in which the body produces too many blood platelets, and against myelofibrosis, a bone marrow disease that disrupts the body’s production of blood cells.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News